Capricor Therapeutics Inc
CAPR
$26.44
-13.03%
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on developing transformative cell and exosome-based therapeutics, primarily targeting Duchenne muscular dystrophy (DMD) and other diseases with high unmet medical needs. The company is a niche player in the rare disease space, distinguished by its allogeneic cardiac-derived cell therapy, CAP-1002 (deramiocel), which is advancing through a pivotal Phase 3 trial. The current investor narrative is overwhelmingly driven by the binary outcome of this late-stage clinical program, with the stock's extreme volatility reflecting the high-risk, high-reward nature of betting on a potential breakthrough therapy for a devastating condition.…
CAPR
Capricor Therapeutics Inc
$26.44
Investment Opinion: Should I buy CAPR Today?
Rating: Hold. The core thesis is that CAPR is an extremely high-risk, binary-event speculation suitable only for a small, risk-capital portion of a portfolio, and the current price after a 335% run-up offers an unfavorable risk/reward balance ahead of the pivotal data.
The supporting evidence is clear: the company is valued at $1.34 billion on zero revenue and negative earnings (trailing PE of -12.77). While the balance sheet is strong (current ratio 9.01), the financials show no commercial progress. The stock's technicals show a loss of short-term momentum (-3.86% over 1 month) after a parabolic move, suggesting consolidation. The enormous spread in analyst revenue estimates ($37M to $1.25B) underscores the profound uncertainty rather than a clear path to value.
The two biggest risks are clinical trial failure and valuation collapse. This Hold rating would upgrade to a Buy only on a significant pullback closer to major support (e.g., below $20) that improves the risk/reward, or on the announcement of positive interim trial data. It would downgrade to a Sell on any negative clinical update or a breakdown below the $20 support level. Relative to its own history and the reality of its financials, the stock is dramatically overvalued, but it may be fairly valued relative to the potential future revenue stream—if and only if the trial succeeds.
Sign up to view all
CAPR 12-Month Price Forecast
The assessment is neutral based on a balance of extreme potential reward against severe and quantifiable risk. The stock's massive appreciation has likely pulled forward much of the success scenario, leaving limited near-term upside without de-risking data, while the downside to the 52-week low is profound. The strong balance sheet is a positive, but it does not mitigate the clinical risk. The stance would upgrade to bullish only upon the release of unequivocally positive Phase 3 data or a partnership at attractive terms. It would turn bearish on any clinical setback, increased short interest, or a breakdown below key technical support around $25.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Capricor Therapeutics Inc's 12-month outlook, with a consensus price target around $34.37 and implied upside of +30.0% versus the current price.
Average Target
$34.37
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$21 - $34
Analyst target range
Analyst coverage is very limited, with only 3 analysts providing estimates, which is typical for a small-cap, clinical-stage biotech and results in higher volatility and less efficient price discovery. The consensus is implicitly bullish based on the substantial estimated future revenue average of $604.6 million and an estimated EPS average of $7.08, though the extremely wide range from an EPS loss of -$1.56 to a profit of $16.85 highlights profound uncertainty. The target price range is not provided in the data, but the enormous spread in revenue estimates (from $37.0 million to $1.25 billion) and EPS forecasts signals exceptionally high conviction dispersion; the high estimates assume successful trial outcomes and strong market adoption, while the low estimates likely factor in clinical failure or significant commercial hurdles.
Bulls vs Bears: CAPR Investment Factors
The evidence is strongly polarized, with the bull case resting entirely on a future clinical catalyst and the bear case grounded in present financial reality and extreme risk. The bear side currently has stronger foundational evidence, as the company lacks revenue, profits, and a stable valuation. However, the bull side is supported by powerful price momentum and a clear, high-reward catalyst. The single most important tension is the binary outcome of the CAP-1002 Phase 3 trial. Its success would validate the speculative premium and unlock multi-billion dollar potential, while its failure would collapse the narrative and the stock price, rendering all other financial metrics irrelevant.
Bullish
- Pivotal Phase 3 Catalyst: The stock's 335.87% one-year gain and parabolic move from ~$5 to over $40 in December 2025 are driven by anticipation for the binary outcome of the CAP-1002 Phase 3 trial in DMD. A successful trial readout could unlock the analyst-estimated average future revenue of $604.6 million, justifying the current $1.34 billion market cap.
- Strong Financial Runway: The company has a robust balance sheet for its stage, with a current ratio of 9.01 indicating ample short-term liquidity and a very low debt-to-equity ratio of 0.07, minimizing financial risk. This provides a multi-year cash runway to fund the pivotal trial without immediate dilution pressure.
- High Analyst Conviction Potential: While only 3 analysts cover the stock, their high-end estimates project an EPS of $16.85 and revenue of $1.25 billion, signaling a subset of experts see blockbuster potential. The average estimated EPS of $7.08, if achieved, would represent a massive inflection from the current trailing EPS of -$0.08.
- Sustained Long-Term Uptrend: Despite recent consolidation, the stock remains in a powerful intermediate-term uptrend, trading at 75% of its 52-week range with a 412.31% six-month gain. The technical structure suggests the market is pricing in a high probability of success, with support well above the 52-week low of $4.30.
Bearish
- Pre-Revenue, Cash-Burning Business: Capricor is a pre-revenue clinical-stage company with negative profitability across all metrics (gross, operating, and net margins of 0%), a negative ROE of -34.35%, and a negative price-to-cash-flow of -0.02. The investment is a pure bet on future data, with no current financial cushion.
- Extreme Valuation Disconnect: The stock trades at a negative trailing PE of -12.77 and an even worse forward PE of -48.87, indicating expected losses will grow. The $1.34 billion valuation is entirely speculative, disconnected from current financials, and vulnerable to severe compression on any clinical setback.
- High Short Interest & Volatility: A short ratio of 7.73 indicates significant bearish bets against the company, likely anticipating trial failure. The stock's inherent risk is underscored by a max drawdown of -67.67% and extreme price swings, such as the recent -10.49% single-day drop from $33.94 to $30.38.
- Binary Clinical Risk Concentration: The entire thesis hinges on one asset, CAP-1002. The wide dispersion in analyst estimates (EPS from -$1.56 to $16.85) highlights profound uncertainty. A failed trial would likely send the stock back toward its 52-week low, representing a potential loss of over 85% from the current price.
CAPR Technical Analysis
The prevailing price trend is a powerful, sustained uptrend characterized by extreme volatility, with the stock posting a staggering 335.87% gain over the past year. As of the latest close at $30.38, the price sits at approximately 75% of its 52-week range ($4.30 to $40.37), indicating it has retreated meaningfully from its highs but remains in a strong intermediate-term uptrend, suggesting a consolidation phase after a parabolic move. Recent momentum shows significant divergence, with a 3-month gain of 22.90% contrasting sharply with a 1-month decline of -3.86%, signaling a loss of short-term momentum and a potential pause or pullback within the larger bullish structure; this is further evidenced by a negative 1-month relative strength of -12.97 against the SPY. Key technical levels are clearly defined, with major support at the 52-week low of $4.30 and immediate resistance at the 52-week high of $40.37; a breakout above $40.37 would signal a resumption of the primary uptrend, while a sustained break below the recent consolidation zone around $30 could indicate deeper correction. The stock's beta of 0.48 suggests it has been less volatile than the market recently, which is atypical for a biotech and may be distorted by the specific period measured, but the enormous 412.31% six-month gain and a max drawdown of -67.67% underscore its inherently high, event-driven risk profile.
Beta
0.37
0.37x market volatility
Max Drawdown
-67.7%
Largest decline past year
52-Week Range
$4-$40
Price range past year
Annual Return
+159.7%
Cumulative gain past year
| Period | CAPR Return | S&P 500 |
|---|---|---|
| 1m | -9.3% | -3.6% |
| 3m | -8.5% | +15.3% |
| 6m | -10.9% | +6.1% |
| 1y | +159.7% | +18.6% |
| ytd | -6.6% | +6.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAPR Fundamental Analysis
As a pre-revenue, clinical-stage biotech, Capricor's fundamental analysis centers on its financial runway and progress toward commercialization, rather than traditional revenue and profit metrics. The company reported a trailing twelve-month net income of -$0.08 per share, a return on equity of -34.35%, and a return on assets of -25.68%, which are expected figures for a company burning cash to fund expensive Phase 3 trials. Profitability metrics are uniformly negative or zero, with gross margin, operating margin, and net margin all at 0%, confirming the absence of commercial product sales; the investment case is entirely predicated on future potential, not current earnings. The balance sheet appears robust for its stage, with a strong current ratio of 9.01 indicating ample short-term liquidity, a very low debt-to-equity ratio of 0.07 minimizing financial risk, and a market capitalization of $1.34 billion providing currency for potential fundraising; however, the negative price-to-cash-flow ratio of -0.02 confirms the company is consuming, not generating, cash to fund operations.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAPR Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric is the Price-to-Sales (PS) ratio; however, the provided PS ratio is 0, indicating no meaningful revenue, so we must rely on forward-looking estimates and market cap context. The market is valuing the company at a $1.34 billion enterprise value based purely on the clinical prospects of CAP-1002, as evidenced by a negative trailing PE of -12.77 and an even more negative forward PE of -48.87, with the widening gap suggesting analysts expect losses to persist or increase as the trial advances. Peer comparison is challenging without industry average multiples, but the valuation is entirely speculative and disconnected from current financials, trading on the potential future revenue stream estimated by analysts to reach an average of $604.6 million. Historical context is limited without historical ratio data, but the stock's 335.87% one-year price appreciation suggests the current valuation is likely at the upper end of its own historical range, pricing in a high probability of clinical success and future commercialization.
PE
-12.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-10.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and fundamental. As a pre-revenue biotech, Capricor burns cash with a negative net income of -$0.08 per share and negative cash flow, entirely dependent on its balance sheet to fund the Phase 3 trial. While the strong current ratio of 9.01 and low debt of 0.07 D/E provide a runway, they do not eliminate the risk of future dilutive financing if the trial is prolonged or requires additional studies. The company has zero revenue diversification, with 100% of its value concentrated in CAP-1002, making it a single-asset bet with no operational hedge.
Market & Competitive Risks center on valuation compression and sector sentiment. Trading at a negative forward PE of -48.87, the stock carries a massive speculative premium that is highly sensitive to clinical news and biotech sector rotations. The stock's beta of 0.48 is misleading given its event-driven nature; the -67.67% max drawdown is a more accurate reflection of its volatility risk. Competitive risks include other companies developing therapies for DMD, which could diminish CAP-1002's market potential even if it is approved. Furthermore, the limited analyst coverage (only 3) results in less efficient price discovery and higher susceptibility to sharp moves on rumor or limited data.
The Worst-Case Scenario is a clear failure of the CAP-1002 Phase 3 trial to meet its primary endpoint. This would immediately invalidate the investment thesis, lead to analyst downgrades, and trigger a rapid unwind of the speculative premium. Given the stock's 52-week low is $4.30, a return to near that level is plausible, representing a downside of approximately -86% from the current price of $30.38. This scenario is quantified by the analyst low EPS estimate of -$1.56, which implies continued significant losses and no near-term path to profitability. An investor could realistically lose most of their capital in this adverse outcome.
FAQ
The key risks are: 1) Clinical Failure Risk: The entire investment hinges on CAP-1002's Phase 3 success; failure could cause an -86% drop to the $4.30 low. 2) Financial Risk: The company is pre-revenue and cash-burning (negative P/CF of -0.02), reliant on its balance sheet with a runway that will eventually require dilution. 3) Valuation Risk: The stock trades at a negative forward PE of -48.87 and is vulnerable to severe multiple compression on any negative news. 4) Market & Liquidity Risk: With only 3 analyst covers and a short ratio of 7.73, the stock is prone to high volatility and sharp downdrafts on sentiment shifts.
The 12-month forecast is a wide range of outcomes centered on the Phase 3 trial results. The base case (50% probability) sees the stock consolidating between $25 and $35 as investors await data. The bull case (25% probability), driven by positive trial results, targets a breakout above the $40.37 high toward $55. The bear case (25% probability), involving trial failure, forecasts a collapse toward the $4.30 to $15 range. The most likely scenario is the base case of volatile consolidation, as the final clinical data may not be available within the next 12 months. The key assumption is that the trial continues without a definitive readout.
CAPR is dramatically overvalued based on any standard financial metric, as it has no revenue (PS ratio of 0) and negative earnings (trailing PE of -12.77). The market is valuing the company at $1.34 billion based purely on the future potential of its lead drug candidate. This valuation implies the market is assigning a significant probability of clinical success and future commercialization. Compared to its own trading history, the stock is likely at the upper end of its range after a 335% one-year gain. Therefore, it is overvalued relative to current fundamentals but may be fairly valued relative to its potential—a distinction that hinges entirely on clinical trial outcomes.
CAPR is not a 'good buy' in the traditional sense of a sound investment with a favorable risk/reward profile. It is a highly speculative biotech wager. For a venture-capital-minded investor allocating a small portion of capital to high-risk opportunities, it could be a buy based on the potential for CAP-1002's success, implied by the analyst average revenue estimate of $604.6 million. However, for the vast majority of investors seeking capital preservation or steady growth, it is a poor choice due to its pre-revenue status, negative earnings, and 86% downside risk to its 52-week low of $4.30.
CAPR is unsuitable for short-term trading for all but the most sophisticated and risk-tolerant traders, due to its extreme event-driven volatility and low beta that masks its true risk. It is theoretically a long-term investment, but only if an investor is willing to hold through the multi-year process of clinical development, regulatory review, and potential commercialization. However, the 'long-term' viability is binary: it will either succeed and become a long-term holding, or fail and become worthless. A suggested minimum holding period is through the Phase 3 data readout, which is the defining event, but investors must be prepared for the possibility of a total loss of capital at that point.